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Abstract 
Bone marrow stromal cells (BMSCs) and osteoclasts (OCs) confer multiple myeloma 
(MM) cell survival through elaborating factors. We demonstrate herein that IL-6 and 
TNF family cytokines, TNFα, BAFF and APRIL, but not IGF-1 cooperatively enhanced 
the expression of the serine/threonine kinase Pim-2 in MM cells. BMSCs and OCs 
up-regulate Pim-2 expression in MM cells largely via the IL-6/STAT3 and NF-κB 
pathway, respectively. Pim-2 siRNA reduces MM cell viability in cocultures with 
BMSCs or OCs. Thus, up-regulation of Pim-2 appears to be a novel anti-apoptotic 
mechanism for MM cell survival. Interestingly, the mTOR inhibitor rapamycin further 
suppresses the MM cell viability in combination with the Pim-2 silencing. The Pim 
inhibitor (Z)-5-(4-propoxybenzylidene) thiazolidine-2, 4-dione and the PI3K inhibitor 
LY294002 cooperatively enhance MM cell death. The Pim inhibitor suppressed 4E-BP1 
phosphorylation along with the reduction of Mcl-1 and c-Myc. Pim-2 may therefore 
become a new target for MM treatment. 
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Introduction 
Multiple myeloma (MM) cells enhance osteoclast (OC) formation and suppress 
osteoblast (OB) differentiation of bone marrow stromal cells. Such effects of MM cells 
not only create destructive bone lesions but also provide a cellular microenvironment to 
protect MM cells from various apoptotic insults.1-5 IL-6 and TNF family cytokines, 
TNFα, BAFF and APRIL, are among predominant anti-apoptotic factors for MM cells 
elaborated by the bone marrow microenvironment surrounding MM.1, 6-8 IL-6 is mainly 
produced by bone marrow stromal cells (BMSCs),1, 6 whereas OCs are a major producer 
of BAFF and APRIL in the MM bone marrow microenvironment.9, 10 The 
serine/threonine kinase Pim-2 has been demonstrated to be transcriptionally 
up-regulated to promote survival of hematopoietic cells in response to ambient growth 
factors and cytokines.11 We demonstrate herein that Pim-2 is up-regulated in MM cells 
by BMSCs and OCs, and acts as an important pro-survival mediator. 
 
 
Materials and methods 
Reagents 
The following reagents were purchased from the indicated manufactures: rh IL-6, BAFF 
and SDF-1α from PEPROTECH EC (London, UK); rh TNFα, APRIL, IGF-1, VEGF, 
neutralizing mouse monoclonal antibodies against IL-6 and against IL-6 receptor from 
R&D Systems (Minneapolis, MN); cucurbitacin I, parthenolide, rapamycin, LY294002 
and the Pim inhibitor (Z)-5-(4-propoxybenzylidene)thiazolidine-2,4-dione from 
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Calbiochem (Darmstadt, Germany); Mouse monoclonal antibody against human Pim-2 
and rabbit polyclonal antibodies against STAT-3 and Mcl-1 from Santa Cruz 
Biotechnology (Santa Cruz, CA); rabbit polyclonal antibodies against phosphorylated 
NFκB p65, NF-κB p65, 4E-BP1, phospohrylated 4E-BP1 (Ser 65), phosphorylated 
4E-BP1 (Thr 37/46)  and phosphorylated STAT-3, mouse monoclonal antibody against 
phosphorylated Bad, rabbit monoclonal antibodies against human Pim-2 and c-Myc, 
horseradish peroxidase (HRP)-conjugated horse anti-mouse IgG and HRP-conjugated 
goat anti-rabbit IgG from Cell Signaling Technology (Beverly, MA); mouse monoclonal 
anti-Bad from BD Transduction Laboratories (Franklin-Lakes, NJ); rabbit anti-β-actin 
from Sigma (St. Louis, MO). 
 
Cells and cultures 
Human non-hematopoietic cell lines, MG63, MCF7 and Colo205, human myeloid cell 
lines, KU812F, HL-60 and U937, human lymphoid cell lines, CEM and IM-9, and 
human MM cell lines, RPMI8226 and U266, were obtained from American Type 
Culture Collection (ATCC) (Rockville, MD). The MM cell line INA6 and MM.1S was 
kindly provided by Dr. Renate Burger (University of Kiel, Kiel, Germany) and Dr. 
Steven Rosen (Northwestern University, Chicago, IL), respectvely. TSPC-1 and OPC 
MM cell lines were established in our laboratory.12 Primary MM cells and BMSCs were 
isolated from fresh bone marrow aspirates from patients with MM and cultured as 
previously described.11 BMSCs were a homogeneous population of spindle-shaped cells 
expressing CD44, CD73, CD90 and CD105, but neither CD45 nor factor VIII. OCs 
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were generated from peripheral blood mononuclear cells (PBMCs) as previously 
reported.11 Cells were cultured in αMEM supplemented with 10% Fetal Bovine Serum 
(FBS), 2 mM of L-Glutamine (Sigma), 100 U/ml of penicillin G and 100 μg/ml of 
streptomycin (Sigma). All procedures involving human specimens were performed with 
written informed consent according to the Declaration of Helsinki and using a protocol 
approved by the Institutional Review Board for human protection.  
 
Western blot analysis  
Cells were collected and lysed in lysis buffer (Cell Signaling) supplemented with 1 mM 
phenylmethylsulfonyl fluoride and protease inhibitor cocktail solution (Sigma). Cell 
lysates were subjected to Western blot analysis as described previously.13 
 
Immunohistochemistry 
Bone marrow clot sections from MM patients were fixed in neutral-buffered formalin 
and embedded in paraffin. Paraffin-embedded tissue sections were deparaffinized and 
hydrated. For antigen retrieval the sections were microwaved in 10mM sodium citrate 
buffer (pH 6.6). After a 10-minute blocking process, the sections were incubated with 
rabbit monoclonal anti-human Pim-2 antibody (Cell Signaling) or control rabbit IgG 
(Vector Laboratories, Burlingame, CA) overnight at 4°C. Immunoreactivity was 
detected by biotinylated secondary antibodies and horseradish peroxidase-conjugated 
streptavidin (DAKO LSAB+ System, HRP; DAKO, Carpinteria, CA) followed by 
diaminobenzidine substrate (DAKO).  
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Quantitative real-time PCR 
RNA isolation and quantitative real-time PCR were performed as described 
previously.13  Primers used were as follows: Human Pim-2 sense 
5’-AGGGATTGAGGATCAGGGGT-3’ and antisense 
5’-CACAGGTTCTGGGAGGAAGG-3’. Human GAPDH, used as a housekeeping gene 
for quantity normalization, sense 5’-AATCCCATCACCATCTTCCA-3’, antisense 
5’-TGGACTCCACGACGTACTCA-3’. 
 
Transfection  
MM cells were transfected with 6-carboxyfluorescein (6-FAM)-labeled Pim-2 short 
interfering RNA (siRNA) (sense, 5’-GUGCCAAACUCAUUGAUUUTT-3’ and 
antisense, 5’-AAAUCAAUGAGUUUGGCACTT-3’) and scrambled siRNA (sense, 
5’-AUCCGCGCGAUAGUACGUATT-3’ and antisense, 
5’-UACGUACUAUCGCGCGGAUTT-3’) (B-Bridge, Mountain View, CA) using a 
Human Nucleofector Kit (Amaxa Biosystems, Cologne, Germany). The transfected 
cells were sorted by a flow cytometer (EPICS ELITE; Beckman Coulter, Brea, CA). 
 
Cell viability assays 
Viable cell numbers were counted by trypan blue dye exclusion assay as we previously 
described.11 Cell viability was also determined by Cell Counting Kit-8 assay 
(DOJINDO, Kumamoto, Japan) according to the manufacture’s instructions. The 
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absorbance of each well was measured at 450 nm with a microtiter plate reader (Model 
450 micro plate reader; Bio-Rad Laboratories, Hercules, CA). Apoptosis was evaluated 
by staining cells with an annexin V-FITC and propidium iodide (PI) labeling kit 
(MEBCYTO Apoptosis Kit; MBL, Nagano, Japan) according to instructions. 
 
Statistical analysis 
Data are expressed as means +/- standard deviation unless otherwise specified. 
Statistical significance was determined by a one-way analysis of variance (ANOVA) 
with Scheffe’s post hoc tests. The minimal level of significance was P=0.05. 
 
 
Results and Discussion 
BMSCs and OCs enhance Pim-2 expression in MM cells 
Pim-2 protein was constitutively expressed at higher levels in MM cell lines and some 
other hematopoietic cell lines than in non-hematopoietic cell lines and normal 
peripheral blood mononuclear cells (Figure 1a and Supplementary Figure 1). Pim-2 
protein expression was also observed in MM cells in bone marrow specimens of 
patients with MM (Figure 1b). Interestingly, Pim-2 mRNA levels were up-regulated 
substantially (about 2- to 9-fold) in all MM cell lines and MM cells from all patients 
with MM when cocultured with BMSCs (Figure 2a upper). Consistently, Pim-2 protein 
levels were also enhanced by coculturing with BMSCs (Figure 2a lower). Although 
PBMC-derived OCs also up-regulated Pim-2 expression in most of these MM cells 
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(Figure 2b), BMSCs more potently enhanced Pim-2 expression in MM cells than OCs. 
These results demonstrate that Pim-2 is over-expressed in MM cells and that BMSCs 
and OCs stimulate Pim-2 expression in MM cells. 
 
IL-6 and TNF family cytokines cooperatively enhance Pim-2 expression in MM 
cells 
To determine the factors responsible for Pim-2 up-regulation in MM cells, we examined 
Pim-2 expression in MM cells under stimulation with anti-apoptotic cytokines 
over-produced in the MM bone marrow microenvironment. IL-6 and TNF family 
cytokines, TNFα, BAFF and APRIL, up-regulated Pim-2 expression in MM cells 
(Figure 3a). Interestingly, IL-6 and these TNF family cytokines cooperatively enhanced 
Pim-2 expression in MM cells (Figure 3a). However, another important anti-apoptotic 
cytokine, IGF-I, did not increase but rather suppressed Pim-2 expression 
(Supplementary Figure 2). SDF-1 and VEGF showed no significant effect. These results 
suggest that IL-6 and these TNF family cytokines are among predominant factors 
responsible for Pim-2 up-regulation in MM cells in the bone marrow microenvironment 
in MM.  
IL-6 induced STAT3 phosphorylation followed by Pim-2 up-regulation in MM 
cells (Supplementary Figure 3). Addition of cucurbitacin I, a STAT3 inhibitor, 
suppressed the Pim-2 up-regulation by IL-6 (Figure 3b). TNFα induced Pim-2 
up-regulation following phosphorylation of NFκB in MM cells (Supplementary Figure 
3). The Pim-2 up-regulation by TNFα was suppressed by an IKKα/β inhibitor, 
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parthenolide, (Figure 3c). Thus, STAT3 and NF-κB activation mediates Pim-2 
up-regulation in MM cells. These results are consistent with the notion that IL-6 and 
these TNF family cytokines act together to up-regulate Pim-2 expression in MM cells in 
the bone marrow microenvironment. However, basal expression levels of Pim-2 were 
associated with neither the levels of phosphorylation of STAT3 nor NF-κB activation in 
MM cell lines without external stimuli (Supplementary Figure 1). Other signaling 
pathways may also be involved in endogenous up-regulation of basal Pim-2 levels in 
MM cells. 
 
Inhibition of IL-6/STAT3 and NF-κB pathways aboshishes Pim-2 up-regulation in 
MM cells by BMSCs and OCs, respectively 
Because BMSCs produce a large amount of IL-6 and regarded as a major source of IL-6 
in the bone marrow microenvironment in MM,1, 6 and because IL-6 potently 
up-regulates Pim-2 expression in MM cells, we next explored the role of IL-6 in the 
Pim-2 up-regulation in MM cells by BMSCs. The up-regulation of Pim-2 mRNA 
expression in INA-6 and RPMI8226 cells by BMSCs was almost completely suppressed 
by antibodies against IL-6 and IL-6 receptor in combination (Figure 3d). The inhibition 
of STAT3 by cucurbitacin I also abolished the Pim-2 up-regulation in MM cells by 
BMSCs (Figure 3e left). The inhibition by LY294002 of a PI3K/Akt pathway, a major 
downstream signaling pathway of IGF-1, did not affect Pim-2 expression in MM cells 
up-regulated by BMSCs (Figure 3e right), which is consistent with the observation with 
no induction of Pim-2 expression in MM cells by IGF-1 (Supplementary Figure 2). 
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Thus, IL-6 appears to be a predominant BMSC-derived factor responsible for Pim-2 
up-regulation in MM cells. The IKKα/β inhibitor parthenolide abolished Pim-2 
up-regulation in MM cells cocultured with OCs (Figure 3f), suggesting a major role of 
the NFκB pathway in Pim-2 up-regulation in MM cells by OCs.  
 
Pim-2 inhibition and rapamycin cooperatively suppress MM cell survival 
To clarify the roles of Pim-2 in MM cell survival, we next examined the effect of Pim-2 
silencing in MM cells. Pim-2 silencing by Pim-2 siRNA reduced Pim-2 expression in 
RPMI8226 cells to about 62% and 29% in the absence and presence of IL-6, 
respectively, compared with that by control siRNA (Supplementary Figure 4a). IL-6, 
BMSCs or OCs are able to enhance the survival of the IL-6-dependent INA-6 cell line, 
which otherwise undergoes apoptosis. The viability of INA-6 cells was partially but 
significantly reduced by Pim-2 silencing in the presence of IL-6, BMSCs or OCs 
(Figure 4a). Because Pim-2 up-regulation is largely independent of the PI3K/Akt 
pathway (Figure 3e), and because the PI3K/Akt pathway is an important survival 
pathway in MM cells14, 15, we examined the effects of inhibition of both Pim-2 and 
PI3K/Akt pathways on MM cell viability in the presence of BMSCs. Rapamycin is an 
inhibitor of mammalian target of rapamycin (mTOR), a downstream signaling molecule 
of the PI3K/Akt pathway. Pim-2 silencing or addition of rapamycin alone partially 
reduced the viability of INA-6 cells supported by BMSCs (Figure 4b left), whereas the 
two treatments in combination further reduced INA-6 cell viability. The combinatory 
treatment also potently suppressed the survival of RPMI8226 cells (Figure 4b right) 
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which can grow in the absence of BMSCs. These results suggest a cooperative role of 
Pim-2 and mTOR pathways in MM cell survival. 
 
The Pim inhibitor (Z)-5-(4-propoxybenzylidene)thiazolidine-2,4-dione suppresses 
MM cell viability 
Because Pim-2 knockdown was partial in MM cells by Pim-2 siRNA due to low 
trasfection efficiency in MM cells, we extended the experiments with the Pim inhibitor 
(Z)-5-(4-propoxybenzylidene)thiazolidine-2,4-dione, which preferentially suppress 
Pim-2 rather than Pim-116,17. The Pim inhibitor dose-dependently suppressed the 
viability of MM cell lines including INA6, RPMI8226, MM.1S, TSPC-1 and OPC 
(Figure 4c). Addition of the Pim inhibitor increased the %distribution of 
annexinV-positive cells in INA-6 cells in the absence or presence of BMSCs (Figure 4d 
in the revised manuscript), suggesting anti-apoptotic activity mediated by the Pim 
pathway. The Pim inhibitor in combination with the PI3K inhibitor LY294002 
cooperatively reduced numbers of viable INA-6 cells both in the absence or presence of 
BMSCs (Figure 4e).  
       We further examined the effects of the Pim inhibitor on phosphorylation of 
4E-BP1 and expression of growth and survival mediators, because the Pim pathway has 
been demonstrated to be responsible for the phosphorylation of 4E-BP1 to trigger 
protein translation for cell growth and survival.11,18 Treatment with the Pim inhibitor 
markedly suppressed the phosphorylation of 4E-BP1 along with the reduction of Mcl-1 
and c-Myc protein levels in INA6 and RPMI8226 cells (Figure 4f). However, 
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phosphorylation of Bad and the levels of other apoptosis-related factors including 
Bcl-xL, Bcl-2 and Bim showed no appreciable change in RPMI8226 cells upon the 
treatment with the Pim inhibitor (Supplementary Figure 4b). Thus, the induction of 
apoptosis by the Pim inhibitor is suggested to be associated at least in part with the 
reduction of phosphorylated 4E-BP1, Mcl-1 and c-Myc.  
 
Conclusion 
The present observations demonstrate that Pim-2 is a novel pro-survival mediator for 
MM cells, and suggest that the MM bone marrow microenvironment up-regulates Pim-2 
expression in MM cells through activation of the JAK2/STAT3 pathway for IL-6 and 
the NF-κB pathway for TNF family cytokines to promote MM cell survival. Therefore, 
Pim-2 over-expressed in MM cells in the MM bone marrow microenvironment appears 
to be an important therapeutic target. IGF-1 is another critical 
microenvironment-derived survival factor for MM cells,14, 15 and inhibition of the 
IGF-1/PI3K/Akt pathway by Akt or mTOR inhibitors has drawn considerable attention 
as a new therapeutic modality against MM.19, 20 Because Pim-2 up-regulation is largely 
independent of the PI3K/Akt pathway (Figure 3e), and because inhibition of Pim-2 and 
PI3K/Akt pathways cooperatively reduce MM cell survival (Figure 4b and 4e), Pim-2 
should be targeted to improve anti-MM efficacy together with PI3K/Akt pathway 
inhibitors. A therapeutic impact of Pim-2 inhibition on MM survival would be further 
warranted when potent specific inhibitors for Pim-2 become available. 
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Figure legends 
 
Figure 1. Pim-2 is constitutively expressed in MM cells. (a) Pim-2 protein expression 
in MM cell lines. Pim-2 protein expression was examined by Western blot analysis in 
various malignant cell lines as well as normal peripheral blood mononuclear cells 
(PBMC). Cell lysates were harvested from human non-hematopoietic cell lines, MG63, 
MCF7 and Colo205, human myeloid cell lines, KU812F, HL-60 and U937, human 
lymphoid cell lines, CEM and IM-9, and human MM cell lines, RPMI8226, U266 and 
INA-6, and PBMC. β-actin was blotted as a loading control. (b) Pim-2 expression in 
primary MM cells. Bone marrow clot sections obtained from 6 patients with MM were 
stained with control IgG (upper) or anti-Pim-2 antibody (lower). Pim-2 protein 
expression was observed in MM cells in all bone marrow specimens. Cells were 
visualized under an Olympus BX50 microscope equipped with UMPlanFI 40X/0.75 
objective lens (Olympus, Tokyo, Japan) to achieve an original magnification of 400X. 
Images were recorded with an Olympus SC35 CCD camera and Viewfinder Lite 
Software (Pixera, Los Gatos, CA). 
 
Figure 2. Pim-2 up-regulation in MM cells by BMSCs and OCs. After co-culturing in 
quadruplicate with BMSCs (1x 105/mL) (a) or PBMC-derived OCs (1x 104/mL) (b) for 
2 days, MM cells were harvested. Pim-2 mRNA expression in primary MM cells and 
MM cell lines was analyzed by real-time RT-PCR (upper). Human GAPDH was used as 
a housekeeping gene for quantity normalization. The results with BMSCs and OCs are 
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expressed as a fold increase from the baseline ratios of Pim-2 mRNA /GAPDH mRNA. 
Pim-2 protein levels were also examined by Western blot analysis (lower). β-actin was 
blotted as a loading control. 
 
Figure 3. Regulation of Pim-2 expression in MM cells. (a) INA-6 cells were cultured 
with rh IL-6 (10 ng/ml), TNFα (10 ng/ml), BAFF (100 ng/ml) and APRIL (100 ng/ml) 
alone or in combination as indicated. (b) The effects of STAT-3 inhibition on Pim-2 
up-regulation in MM cells by IL-6. INA-6 cells were cultured in the absence or 
presence of rhIL-6 at 10 ng/mL. The JAK/STAT3 inhibitor cucurbitacin I was added at 
10 μM as indicated. Total RNA and cell lysates were collected from the MM cells after 
culturing for 4 and 24 hours, respectively. Pim-2 mRNA expression in MM cells was 
analyzed by real-time RT-PCR (left). The results are expressed as ratios of Pim-2 
mRNA /GAPDH mRNA. *, p<0.05. Pim-2 protein levels were also examined by 
Western blot analysis (right). β-actin was blotted as a loading control. (c) The effects of 
NF-κB inhibition on Pim-2 up-regulation in MM cells by TNFα. RPMI8226 cells were 
cultured in the absence or presence of rhTNFα at 10 ng/mL. The IKKα/β inhibitor 
parthenolide was added at 10 μM as indicated. Total RNA and cell lysates were 
collected from the MM cells after culturing for 4 and 24 hours, respectively. Pim-2 
mRNA expression in MM cells was analyzed by real-time RT-PCR(left). *, p<0.05. 
Pim-2 protein levels were also examined by Western blot analysis (right). (d) The 
effects of IL-6 blockade on Pim-2 up-regulation in MM cells by BMSCs. Pim-2 mRNA 
expression in INA-6 and RPMI8226 cells was analyzed by real-time RT-PCR after 
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co-culturing with BMSCs for 2 days in the absence or presence of neutralizing anti-IL-6 
and anti-IL-6 receptor antibodies in combination. (e) The effects of STAT-3 inhibition 
on Pim-2 up-regulation in MM cells by BMSCs. INA-6 cells were cultured alone or 
with BMSCs for 4 hours in the absence or presence of cucurbitacin I at different 
concentrations as indicated as well as the PI3K/Akt inhibitor LY294002 at 10 μM. (f) 
The effects of NF-κB inhibition on Pim-2 up-regulation in MM cells by OCs. TSPC-1 
MM cells were cultured alone or with PBMC-derived OCs (1x 104/mL). Parthenolide 
was added at 10 μM as indicated. Total RNA was extracted from the MM cells after 
culturing for 4 hours. Pim-2 mRNA expression in MM cells was analyzed by real-time 
RT-PCR. The results are expressed as ratios of Pim-2 mRNA /GAPDH mRNA. *, 
p<0.05.  
 
Figure 4. Pim-2 inhibition suppresses MM cell survival. (a) The suppression of MM 
cell viability by Pim-2 knockdown. INA-6 cells were transfected with either 
6-FAM-labeled scrambled (control) or Pim-2 siRNA. The transfected cells were sorted 
by a flow cytometer, and cultured in quadruplicate in the absence or presence of rhIL-6 
at 10 ng/mL, or cocultured with BMSCs or OCs. INA-6 cells were harvested after 
culturing for 2 days and their viability was analyzed. The results are expressed as % 
change from the baseline. *, p<0.05. (b) Cooperative effects of Pim-2 siRNA and 
rapamycin on MM cell survival. INA-6 (left) and RPMI8226 (right) cells were 
transfected with either control or Pim-2 siRNA. INA-6 cells were cocultured with 
BMSCs. RPMI8226 cells were cultured alone in serum-depleted media. Rapamycin was 
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added at 10 nM as indicated. After culturing for 2 days, MM cells were harvested and 
their viability was analyzed. Representative results from 3 independent experiments are 
shown. The results are expressed as % change from the baseline. (c) Suppression of 
MM cell viability by the Pim inhibitor 
(Z)-5-(4-propoxybenzylidene)thiazolidine-2,4-dione. INA6, RPMI8226, MM.1S, 
TSPC-1 and OPC MM cell lines were cultured in triplicate at 3 x 105/mL in the absence 
or presence of (Z)-5-(4-propoxybenzylidene)thiazolidine-2,4-dione as the indicated 
concentrations. After culturing for 48 hours, the viability of MM cells was analyzed. 
The results were expressed as %change of viable cell numbers in the presence of the 
Pim inhibitor as indicated concentrations from those in control. (d) Induction of 
apoptosis by the Pim inhibition. INA-6 cells were cultured alone or with BMSCs. 
(Z)-5-(4-propoxybenzylidene) thiazolidine-2,4-dione was added as indicated. After 
culturing for 24 hours, induction of apoptosis was analyzed by AnnexinV and PI dual 
staining. (e) Suppression of MM cell viability by the Pim inhibition in combination with 
LY294002. INA-6 cells were cultured alone or cocultured with BMSCs. 
(Z)-5-(4-propoxybenzylidene) thiazolidine-2,4-dione, LY294002, or both in 
combination were added as indicated. After culturing for 24 hours, the viability of MM 
cells was analyzed. The results were expressed as %change from viable cell numbers in 
INA6 cells cultured alone. (f) The reduction of phosphorylated 4E-BP1, Mcl-1 and 
c-Myc by the Pim inhibition. INA6 and RPMI8226 cells were cultured in 0.1% FBS in 
the absence or presence of (Z)-5-(4-propoxybenzylidene) thiazolidine-2,4-dione at 50 
μM. Cell lysates were collected after culturing for 6 hours. Protein levels of 
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phosphorylated 4E-BP1, Mcl-1 and c-Myc were analyzed by Western blot analysis. 
β-actin was blotted as a loading control. 
 
 








